Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.91
W. Tay, Gerald Low Jun Teck, J. Loo, Le Shaun Ang, Y. Wong
Background Endoscopic variceal ligation (EVL) is a common procedure for primary and secondary prevention of variceal bleeding in cirrhosis patients. As portal vein thrombosis is associated with a higher risk of variceal bleeding and decompensation in cirrhosis patients, anticoagulation may be considered in these patients. However, it is uncertain if continuing anticoagulation during EVL may significantly increase the risk of bleeding. To address this gap, we performed a systematic review and meta-analysis to evaluate the safety of continuing anticoagulation during EVL. The primary outcome was the bleeding risk following EVL. Secondary outcomes were mortality following EVL and length of stay (LOS). Methods We performed a systematic search of 4 electronic databases (PubMed/MEDLINE, EMBASE, Cochrane library, and ClinicalTrial.gov) up to May 21, 2021 using both free text and MeSH terms. We included all studies that reported the 4-week rebleeding rate in cirrhosis patients during EVL, regardless of study design, language, publication types or status. The pooled relative risk (RR), mean difference (MD) and 95% confidence interval (95%CI) of study outcomes were estimated using Review Manager in a random-effect model. Results A total of six studies (5,102 subjects, 1,028 received anticoagulation) fulfilled our inclusion criteria. The mean (standard deviation) MELD and Child-Pugh score were 18 (5.5) and 7 (1.6), respectively. Follow-up duration ranged from 6 to 196 weeks. The overall pooled risk of bleeding and mortality was 8.2% (95%CI: 6.6%-10.0%) and 8.6% (95%CI: 4.2%-15.3%), respectively. Mean number of bands deployed per session was similar between the anticoagulation and control group. Continuation of anticoagulants during EVL was not associated with a higher pooled risk of bleeding (RR: 0.90, 95%CI: 0.71-1.15, I2 =0%) and mortality (RR: 1.16, 95%CI: 0.22-6.19) following EVL. However, continuing anticoagulation was associated with a shorter LOS (3.9 days, 95%CI: -7.35 to -0.48 days, I2 =0%). All studies had a low risk of bias except for one. Conclusions In cirrhosis patients undergoing EVL, continuing anticoagulation was safe without a significant increase in bleeding and mortality.
{"title":"IDDF2021-ABS-0112 Safety of continuing anticoagulation during endoscopic variceal ligation in cirrhosis patients: a systematic review and meta-analysis","authors":"W. Tay, Gerald Low Jun Teck, J. Loo, Le Shaun Ang, Y. Wong","doi":"10.1136/gutjnl-2021-iddf.91","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.91","url":null,"abstract":"Background Endoscopic variceal ligation (EVL) is a common procedure for primary and secondary prevention of variceal bleeding in cirrhosis patients. As portal vein thrombosis is associated with a higher risk of variceal bleeding and decompensation in cirrhosis patients, anticoagulation may be considered in these patients. However, it is uncertain if continuing anticoagulation during EVL may significantly increase the risk of bleeding. To address this gap, we performed a systematic review and meta-analysis to evaluate the safety of continuing anticoagulation during EVL. The primary outcome was the bleeding risk following EVL. Secondary outcomes were mortality following EVL and length of stay (LOS). Methods We performed a systematic search of 4 electronic databases (PubMed/MEDLINE, EMBASE, Cochrane library, and ClinicalTrial.gov) up to May 21, 2021 using both free text and MeSH terms. We included all studies that reported the 4-week rebleeding rate in cirrhosis patients during EVL, regardless of study design, language, publication types or status. The pooled relative risk (RR), mean difference (MD) and 95% confidence interval (95%CI) of study outcomes were estimated using Review Manager in a random-effect model. Results A total of six studies (5,102 subjects, 1,028 received anticoagulation) fulfilled our inclusion criteria. The mean (standard deviation) MELD and Child-Pugh score were 18 (5.5) and 7 (1.6), respectively. Follow-up duration ranged from 6 to 196 weeks. The overall pooled risk of bleeding and mortality was 8.2% (95%CI: 6.6%-10.0%) and 8.6% (95%CI: 4.2%-15.3%), respectively. Mean number of bands deployed per session was similar between the anticoagulation and control group. Continuation of anticoagulants during EVL was not associated with a higher pooled risk of bleeding (RR: 0.90, 95%CI: 0.71-1.15, I2 =0%) and mortality (RR: 1.16, 95%CI: 0.22-6.19) following EVL. However, continuing anticoagulation was associated with a shorter LOS (3.9 days, 95%CI: -7.35 to -0.48 days, I2 =0%). All studies had a low risk of bias except for one. Conclusions In cirrhosis patients undergoing EVL, continuing anticoagulation was safe without a significant increase in bleeding and mortality.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84837802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.92
K. Ng, N. Cheng, H. Lok, C. Chong, J. Wong, Kit-fai Lee
{"title":"IDDF2021-ABS-0116 Surgical treatment for non-colorectal non-neuroendocrine liver metastases: a systematic review and meta-analysis","authors":"K. Ng, N. Cheng, H. Lok, C. Chong, J. Wong, Kit-fai Lee","doi":"10.1136/gutjnl-2021-iddf.92","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.92","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"127 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72863543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IDDF2021-ABS-0190 Figure 1ConclusionsThe development of a standardised workflow can lead to improvement in anti-HBs testing and compliance to vaccination post-LT. These findings may be useful for other patients who are on long-term immunosuppression. Continual efforts from the multidisciplinary team are required to ensure the sustainability of effect.
{"title":"IDDF2021-ABS-0190 Improving hepatitis B vaccination and response rate in liver transplant recipients","authors":"Shirley Huey Shin, Bong, Elaine Ah Gi, Lo, Eunice Xiang Xuan, Tan, Guan-Huei, Lee","doi":"10.1136/gutjnl-2021-IDDF.102","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-IDDF.102","url":null,"abstract":"IDDF2021-ABS-0190 Figure 1ConclusionsThe development of a standardised workflow can lead to improvement in anti-HBs testing and compliance to vaccination post-LT. These findings may be useful for other patients who are on long-term immunosuppression. Continual efforts from the multidisciplinary team are required to ensure the sustainability of effect.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88070043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.80
H. Janssen, P. Lampertico, Chien-Hung Chen, J. Heo, C. Fournier, S. Ahn, Tak Yin Owen Tsang, C. Coffin, Yi-Hsang Huang, G. Marchesini, A. Hui, M. Elkhashab, Sayed Jafri, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, V. Suri, J. Flaherty, A. Gaggar, D. Brainard, W. Chuang, K. Agarwal, E. Gane, Y. Lim
{"title":"IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)","authors":"H. Janssen, P. Lampertico, Chien-Hung Chen, J. Heo, C. Fournier, S. Ahn, Tak Yin Owen Tsang, C. Coffin, Yi-Hsang Huang, G. Marchesini, A. Hui, M. Elkhashab, Sayed Jafri, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, V. Suri, J. Flaherty, A. Gaggar, D. Brainard, W. Chuang, K. Agarwal, E. Gane, Y. Lim","doi":"10.1136/gutjnl-2021-iddf.80","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.80","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88593064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.83
Thuy Trang Ha, M. Pham, Ngoc Anh Trang
{"title":"IDDF2021-ABS-0083 Assessment pre- and post-treatment quality of life by eortc QLQ-30 questionnaire in patients with hepatocellular carcinoma at hanoi medical university, Vietnam","authors":"Thuy Trang Ha, M. Pham, Ngoc Anh Trang","doi":"10.1136/gutjnl-2021-iddf.83","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.83","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76990486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.82
S. Ahn, J. Kao, P. Lampertico, A. Ramji, S. Fung, W. Chuang, Y. Kim, Chi-yi Chen, E. Tam, H. Bae, Xiaoli Ma, June-Sung Lee, Carol Yee Kwan Chan, L. Yee, S. Sethi, J. Flaherty, Yang Zhao, A. Gaggar, H. Hann, Y. Lim, H. Chan
{"title":"IDDF2021-ABS-0080 96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity","authors":"S. Ahn, J. Kao, P. Lampertico, A. Ramji, S. Fung, W. Chuang, Y. Kim, Chi-yi Chen, E. Tam, H. Bae, Xiaoli Ma, June-Sung Lee, Carol Yee Kwan Chan, L. Yee, S. Sethi, J. Flaherty, Yang Zhao, A. Gaggar, H. Hann, Y. Lim, H. Chan","doi":"10.1136/gutjnl-2021-iddf.82","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.82","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"198 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86596435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.72
M. Pham, N. Tran
{"title":"IDDF2021-ABS-0050 Validation of platelet-albumin- bilirubin (PALBI) score for predicting overall survival of hepatocellular carcinoma","authors":"M. Pham, N. Tran","doi":"10.1136/gutjnl-2021-iddf.72","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.72","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79710675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.100
Sherilyn Zi Hui Liew, J. H. Koh, Gin-Kee Ng, H. Liu, Y. Tam, A. Gottardi, Y. Wong
{"title":"IDDF2021-ABS-0172 Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis","authors":"Sherilyn Zi Hui Liew, J. H. Koh, Gin-Kee Ng, H. Liu, Y. Tam, A. Gottardi, Y. Wong","doi":"10.1136/gutjnl-2021-iddf.100","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.100","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88941042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.61
C. Ng, J. Xiao, Lincoln Kai En Lim, D. Tan, W. Lim, Cyrus S. H. Ho, E. Tan, A. Sanyal, M. Muthiah
IDDF2021-ABS-0008 Figure 1 Abstracts A64 Gut 2021;70(Suppl 2):A1–A150 on S etem er 1, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F 61 on 2 S etem er 221. D ow nladed fom aimed to assess the association between depression and NAFLD. Methods A search of the literature was conducted on Medline and Embase databases to identify articles relating to NAFLD and depression. A meta-analysis of proportions was conducted using the generalized linear mix model with Copper Pearson intervals to stabilize the variance. Risk factors were analyzed using the odds ratios and mean difference for dichotomous and continuous variables respectively. To compare between the rate of depression between NAFLD (non-alcholic fatty liver disease) and NASH (nonalcoholic steatohepatitis), the relative risks (RR) were calculated using the depression in NASH vs NAFLD as the ratio of the pooled proportion and confidence interval by the Katz-logarithmic method. Results Of 1315 unique abstracts identified, 10 articles involving 2,041,752 NAFLD patients were included (IDDF2021ABS-0008 Figure 1. Overall Prevalence of Depression in NAFLD). In a pooled analysis of studies, there was a significant relationship between the diagnosis of depression and NAFLD (OR: 1.29, CI: 1.02 1.64, p=0.03). The overall pooled prevalence of depression in NAFLD was14.39% (CI: 8.89% 22.45%). The prevalence of depression in nonalcoholic steatohepatitis (NASH) is 40.68% (CI: 25.11% 58.37%), significantly higher than that in NAFLD at 14.39% (CI: 8.89% 22.45%). Compared to NAFLD, patients with NASH had a significantly higher risk of depression (RR: 2.83, CI: 2.41 3.32, p <0.001). Diabetes, BMI, female sex, history of smoking and history of lung disease were significant risk factors associated with depression in NAFLD patients and depression in NAFLD patients was an independent predictor of all-cause 1-year mortality. Conclusions To our knowledge, this is the first meta-analysis to describe a positive association between NAFLD and depression with an increasing rate of depression in NASH compared to NAFLD (IDDF2021-ABS-0008 Figure 2. Graphical Depiction of the Overall Results). However, more studies are required to observe the impact of depression and clinical outcomes in NAFLD. IDDF2021-ABS-0010 A META-ANALYSIS AND METAREGRESSION BETWEEN LIVER RESECTION AND LIVER TRANSPLANT WITHIN MILIAN CRITERIA Cheng Han Ng*, Jin Hean Koh, Yuki Ong, Wen Hui Lim, Darren Jun Hao Tan, Mark Muthiah, Nicholas Syn, Brian Goh, Daniel Huang. Yong Loo Lin School of Medicine, Singapore; Singapore General Hospital, Singapore 10.1136/gutjnl-2021-IDDF.62 Background Hepatocellular carcinoma (HCC) is the dominant form of primary liver cancer and a leading cause of cancer globally. Liver transplantation (LT) confers excellent long-term survival outcomes, but its effectiveness is hampered by the dire shortage of liver allografts. Liver resection (LR) is a promising alternative due to favorable
摘要A64 Gut 2021;70(补品2):A1-A150在S etem er 1上，2021按最大。P由赖特保护。http /直觉。jj.com / gt:首次发表为10.113utjnl-2021-ID D F 61, 2月1日第221期。本研究旨在评估抑郁症与NAFLD之间的关系。方法在Medline和Embase数据库中检索与NAFLD和抑郁症相关的文献。采用广义线性混合模型铜Pearson区间进行比例的元分析以稳定方差。危险因素分别采用二分变量和连续变量的比值比和均数差进行分析。为了比较NAFLD(非酒精性脂肪性肝病)和NASH(非酒精性脂肪性肝炎)之间的抑郁率，使用NASH与NAFLD的抑郁作为合并比例和置信区间的比值，通过katz -对数方法计算相对风险(RR)。结果在鉴定的1315篇独特摘要中，纳入了10篇文章，涉及2,041,752例NAFLD患者(IDDF2021ABS-0008)。NAFLD患者抑郁的总体患病率。在一项研究的汇总分析中，抑郁症的诊断与NAFLD之间存在显著关系(OR: 1.29, CI: 1.02 - 1.64, p=0.03)。NAFLD患者抑郁的总总患病率为14.39% (CI: 8.89% - 22.45%)。非酒精性脂肪性肝炎(NASH)患者抑郁患病率为40.68% (CI: 25.11% ~ 58.37%)，显著高于NAFLD患者的14.39% (CI: 8.89% ~ 22.45%)。与NAFLD相比，NASH患者发生抑郁的风险明显更高(RR: 2.83, CI: 2.41 3.32, p <0.001)。糖尿病、BMI、女性、吸烟史和肺部疾病史是NAFLD患者抑郁相关的重要危险因素，NAFLD患者抑郁是1年全因死亡率的独立预测因子。据我们所知，这是第一个描述NAFLD和抑郁症之间正相关的荟萃分析，与NAFLD相比，NASH中抑郁症的发生率增加(IDDF2021-ABS-0008图2)。整体结果的图形描述)。然而，需要更多的研究来观察抑郁症对NAFLD的影响和临床结果。肝切除和肝移植在MILIAN标准下的meta分析和meta回归分析吴成汉*，Koh Jin Hean, Ong Yuki, Lim Wen Hui, Darren Jun Hao Tan, Mark Muthiah, Nicholas Syn, Brian Goh, Daniel Huang。新加坡永禄林医学院;新加坡总医院，新加坡10.1136/gutjnl-2021-IDDF.62肝细胞癌(HCC)是原发性肝癌的主要形式，也是全球癌症的主要原因。肝移植(LT)提供了良好的长期生存结果，但其有效性受到同种异体肝脏移植严重短缺的阻碍。肝切除(LR)是一种很有希望的替代方法，因为它具有良好的长期预后。我们试图进行一项荟萃分析，以比较米兰标准下肝细胞癌肝移植和肝切除的生存结果。方法检索Medline和Embase数据库，比较MC内HCC患者肝移植和肝移植后的生存数据。使用DerSimonian和Laird随机效应模型进行风险比(HR)荟萃分析，比较肝移植和肝移植患者的总生存期(OS)和无病生存期(DFS)。肠道2021;70(补充2):A1-A150 A65在S etem er 1上，2021按最大。P由赖特保护。http /直觉。jj.com / gt:首次发表为10.113utjnl-2021-ID D F 61, 2月1日第221期。我们从
{"title":"IDDF2021-ABS-0008 Is fatty liver associated with depression? A meta-analysis and systematic review on prevalence, risk factors and outcomes of depression and non-alcoholic fatty liver disease","authors":"C. Ng, J. Xiao, Lincoln Kai En Lim, D. Tan, W. Lim, Cyrus S. H. Ho, E. Tan, A. Sanyal, M. Muthiah","doi":"10.1136/gutjnl-2021-iddf.61","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.61","url":null,"abstract":"IDDF2021-ABS-0008 Figure 1 Abstracts A64 Gut 2021;70(Suppl 2):A1–A150 on S etem er 1, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F 61 on 2 S etem er 221. D ow nladed fom aimed to assess the association between depression and NAFLD. Methods A search of the literature was conducted on Medline and Embase databases to identify articles relating to NAFLD and depression. A meta-analysis of proportions was conducted using the generalized linear mix model with Copper Pearson intervals to stabilize the variance. Risk factors were analyzed using the odds ratios and mean difference for dichotomous and continuous variables respectively. To compare between the rate of depression between NAFLD (non-alcholic fatty liver disease) and NASH (nonalcoholic steatohepatitis), the relative risks (RR) were calculated using the depression in NASH vs NAFLD as the ratio of the pooled proportion and confidence interval by the Katz-logarithmic method. Results Of 1315 unique abstracts identified, 10 articles involving 2,041,752 NAFLD patients were included (IDDF2021ABS-0008 Figure 1. Overall Prevalence of Depression in NAFLD). In a pooled analysis of studies, there was a significant relationship between the diagnosis of depression and NAFLD (OR: 1.29, CI: 1.02 1.64, p=0.03). The overall pooled prevalence of depression in NAFLD was14.39% (CI: 8.89% 22.45%). The prevalence of depression in nonalcoholic steatohepatitis (NASH) is 40.68% (CI: 25.11% 58.37%), significantly higher than that in NAFLD at 14.39% (CI: 8.89% 22.45%). Compared to NAFLD, patients with NASH had a significantly higher risk of depression (RR: 2.83, CI: 2.41 3.32, p <0.001). Diabetes, BMI, female sex, history of smoking and history of lung disease were significant risk factors associated with depression in NAFLD patients and depression in NAFLD patients was an independent predictor of all-cause 1-year mortality. Conclusions To our knowledge, this is the first meta-analysis to describe a positive association between NAFLD and depression with an increasing rate of depression in NASH compared to NAFLD (IDDF2021-ABS-0008 Figure 2. Graphical Depiction of the Overall Results). However, more studies are required to observe the impact of depression and clinical outcomes in NAFLD. IDDF2021-ABS-0010 A META-ANALYSIS AND METAREGRESSION BETWEEN LIVER RESECTION AND LIVER TRANSPLANT WITHIN MILIAN CRITERIA Cheng Han Ng*, Jin Hean Koh, Yuki Ong, Wen Hui Lim, Darren Jun Hao Tan, Mark Muthiah, Nicholas Syn, Brian Goh, Daniel Huang. Yong Loo Lin School of Medicine, Singapore; Singapore General Hospital, Singapore 10.1136/gutjnl-2021-IDDF.62 Background Hepatocellular carcinoma (HCC) is the dominant form of primary liver cancer and a leading cause of cancer globally. Liver transplantation (LT) confers excellent long-term survival outcomes, but its effectiveness is hampered by the dire shortage of liver allografts. Liver resection (LR) is a promising alternative due to favorable","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89698910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：